Morning, Tuesday, 16th July 2019
THIS EVENT IS CPD CERTIFIED
This conference will be a timely opportunity to discuss the key issues for biosimilar use in the NHS - looking at the next steps for development, commissioning, and workforce and patient engagement.
Delegates will consider the progress of biosimilar use in the NHS and the role of Regional Medicines Optimisation Committees in coordinating uptake, following NHS England’s commitment to reduce spending on medicines by £300m by 2021 through increased use of biosimilars, as outlined in the Commissioning framework for biological medicines.
They will discuss priorities for addressing unwarranted variation in use within the NHS, looking at how workforce engagement can be improved and the impact of prescribing incentive schemes - as well as improving patient awareness of biosimilars, and how best to inform patients and include them in decisions around switching treatments.
Following the inclusion of biosimilars in the new Voluntary Scheme for Branded Medicines Pricing and Access, attendees will also assess the effect of payment mechanisms and price controls on competition in the marketplace and the prescribing of biosimilars.
Further sessions consider priorities for encouraging the development of new biosimilars in the UK with the increased investment through the Life Sciences Sector Deal and the next steps for promoting the uptake of new biosimilars in the NHS.
The agenda also discusses the next steps for regulation and the future relationship between the European Medicines Agency and the MHRA after Brexit.